Thaera Greg M, Wellik Kay E, Barrs David M, Dunckley Erika D Driver, Wingerchuk Dean M, Demaerschalk Bart M
Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
Neurologist. 2010 Mar;16(2):138-40. doi: 10.1097/NRL.0b013e3181d35775.
: Bell palsy is idiopathic peripheral facial weakness that typically resolves without severe clinical sequelae. Treatment with corticosteroids and antiviral drugs is often initiated to improve the likelihood of a favorable outcome.
: Are corticosteroid and antiviral medications effective in the treatment of Bell palsy?
: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a structured question, search strategy, critical appraisal, results, evidence summary, commentary, pre- and postassessment, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and a clinical content expert in the field of Otolaryngology.
: The largest (18 trials involving 2786 patients) current systematic review and meta-analysis for pharmacologic treatment of Bell palsy was selected for appraisal. The meta-analysis demonstrated a clear benefit of oral corticosteroids, alone, in preventing unsatisfactory recovery of facial weakness (relative risk, 0.69 [95% confidence interval {CI}, 0.55-0.87], number needed to treat 11 [95% CI, 8-25]). Treatment with antiviral medication, alone, was not associated with a reduced risk of unsatisfactory recovery. When administered concurrently with corticosteroids, antiviral treatments displayed a trend toward reduced risk of unsatisfactory recovery, compared with corticosteroids alone (relative risk, 0.75 [95% CI, 0.56-1.00]).
: Corticosteroids effectively reduce the risk of an unfavorable outcome in Bell palsy. Antiviral agents, when administered concurrently with corticosteroids, may result in additional benefit.
贝尔面瘫是一种特发性周围性面神经麻痹,通常可自行缓解,无严重临床后遗症。常采用皮质类固醇和抗病毒药物治疗,以提高获得良好预后的可能性。
皮质类固醇和抗病毒药物治疗贝尔面瘫是否有效?
通过制定结构化的严格评价主题来解决该目的。这包括一个带有结构化问题的临床病例、检索策略、严格评价、结果、证据总结、评论、前后评估以及底线结论。参与者包括顾问和住院神经科医生、医学图书馆员、临床流行病学家以及耳鼻喉科领域的临床内容专家。
选择了目前关于贝尔面瘫药物治疗的最大规模(18项试验,涉及2786例患者)的系统评价和荟萃分析进行评价。荟萃分析表明,单独使用口服皮质类固醇在预防面部无力恢复不佳方面有明显益处(相对危险度,0.69[95%置信区间{CI},0.55 - 0.87],需治疗人数11[95%CI,8 - 25])。单独使用抗病毒药物治疗与恢复不佳风险降低无关。与单独使用皮质类固醇相比,抗病毒治疗与皮质类固醇同时使用时,显示出恢复不佳风险降低的趋势(相对危险度,0.75[95%CI,0.56 - 1.00])。
皮质类固醇可有效降低贝尔面瘫不良预后的风险。抗病毒药物与皮质类固醇同时使用可能会带来额外益处。